The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus

Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomić, Draško, Davidović, Davor, Szasz, Attila Marcel, Rezeli, Melinda, Pirkić, Boris, Petrik, Jozsef, Vrca, Vesna Bačić, Janđel, Vladimir, Lipić, Tomislav, Skala, Karolj, Mesarić, Josip, Periša, Marija Milković, Šojat, Zorislav, Rogina, Branka Medved
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847290/
https://www.ncbi.nlm.nih.gov/pubmed/33553571
http://dx.doi.org/10.1016/j.imu.2021.100529
_version_ 1783644901889540096
author Tomić, Draško
Davidović, Davor
Szasz, Attila Marcel
Rezeli, Melinda
Pirkić, Boris
Petrik, Jozsef
Vrca, Vesna Bačić
Janđel, Vladimir
Lipić, Tomislav
Skala, Karolj
Mesarić, Josip
Periša, Marija Milković
Šojat, Zorislav
Rogina, Branka Medved
author_facet Tomić, Draško
Davidović, Davor
Szasz, Attila Marcel
Rezeli, Melinda
Pirkić, Boris
Petrik, Jozsef
Vrca, Vesna Bačić
Janđel, Vladimir
Lipić, Tomislav
Skala, Karolj
Mesarić, Josip
Periša, Marija Milković
Šojat, Zorislav
Rogina, Branka Medved
author_sort Tomić, Draško
collection PubMed
description Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19 patients in moderately severe and severe condition is warranted.
format Online
Article
Text
id pubmed-7847290
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78472902021-02-01 The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus Tomić, Draško Davidović, Davor Szasz, Attila Marcel Rezeli, Melinda Pirkić, Boris Petrik, Jozsef Vrca, Vesna Bačić Janđel, Vladimir Lipić, Tomislav Skala, Karolj Mesarić, Josip Periša, Marija Milković Šojat, Zorislav Rogina, Branka Medved Inform Med Unlocked Article Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19 patients in moderately severe and severe condition is warranted. The Authors. Published by Elsevier Ltd. 2021 2021-01-30 /pmc/articles/PMC7847290/ /pubmed/33553571 http://dx.doi.org/10.1016/j.imu.2021.100529 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Tomić, Draško
Davidović, Davor
Szasz, Attila Marcel
Rezeli, Melinda
Pirkić, Boris
Petrik, Jozsef
Vrca, Vesna Bačić
Janđel, Vladimir
Lipić, Tomislav
Skala, Karolj
Mesarić, Josip
Periša, Marija Milković
Šojat, Zorislav
Rogina, Branka Medved
The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title_full The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title_fullStr The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title_full_unstemmed The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title_short The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus
title_sort screening and evaluation of potential clinically significant hiv drug combinations against the sars-cov-2 virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847290/
https://www.ncbi.nlm.nih.gov/pubmed/33553571
http://dx.doi.org/10.1016/j.imu.2021.100529
work_keys_str_mv AT tomicdrasko thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT davidovicdavor thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT szaszattilamarcel thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT rezelimelinda thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT pirkicboris thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT petrikjozsef thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT vrcavesnabacic thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT janđelvladimir thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT lipictomislav thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT skalakarolj thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT mesaricjosip thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT perisamarijamilkovic thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT sojatzorislav thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT roginabrankamedved thescreeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT tomicdrasko screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT davidovicdavor screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT szaszattilamarcel screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT rezelimelinda screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT pirkicboris screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT petrikjozsef screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT vrcavesnabacic screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT janđelvladimir screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT lipictomislav screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT skalakarolj screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT mesaricjosip screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT perisamarijamilkovic screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT sojatzorislav screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus
AT roginabrankamedved screeningandevaluationofpotentialclinicallysignificanthivdrugcombinationsagainstthesarscov2virus

Ejemplares similares